IRCT2016041125211N1
Completed
Phase 3
Radiologic response rate of chemoradiotherapy in inoperable head and neck squamous cell carcinoma; weekly versus triweekly cisplatin schedule
ConditionsCondition 1: Head and neck tumor. Condition 2: Head and neck tumor. Condition 3: Head and neck tumor. Condition 4: Head and neck tumor. Condition 5: Head and neck tumor. Condition 6: Head and neck tumor. Condition 7: Head and neck tumor. Condition 8: Head and neck tumor. Condition 9: Head and neck tumor. Condition 10: Head and neck tumor. Condition 11: Head and neck tumor. Condition 12: Head and neck tumor.Malignant neoplasm of oropharynxMalignant neoplasm of palateMalignant neoplasm of floor of mouthMalignant neoplasm of other and unspecified parts of tongueMalignant neoplasm of other and unspecified parts of mouthMalignant neoplasm of gumMalignant neoplasm of lipMalignant neoplasm of base of tongueMalignant neoplasm of nasopharynxMalignant neoplasm of piriform sinusMalignant neoplasm of hypopharynxMalignant neoplasm of other and ill-defined sites in the lip,oral cavity and pharynx
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Condition 1: Head and neck tumor. Condition 2: Head and neck tumor. Condition 3: Head and neck tumor. Condition 4: Head and neck tumor. Condition 5: Head and neck tumor. Condition 6: Head and neck tumor. Condition 7: Head and neck tumor. Condition 8: Head and neck tumor. Condition 9: Head and neck tumor. Condition 10: Head and neck tumor. Condition 11: Head and neck tumor. Condition 12: Head and neck tumor.
- Sponsor
- Ahvaz University Of Medical Sciences
- Enrollment
- 63
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •( Pathologic report of Squamous.cell.carcinoma ; Age 18\- 70 years ; ECOG performance status of 0\-1; No distant metastasis; WBC equal to more than 4000; PLT equal to more than 100000; Hb equal to more than 10; Serum Cr less than 1\.5 ; Serum aminotransferase less than twice of normal range.) (Exclusion criteria: Sever medical or psychiatric disorder; Patient who dose not have a good fallow up.)
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 2
FOLFOXIRI With or Without Intensification for Rectal CancerRectal CancerNCT03997435CCTU72
Completed
Phase 2
A phase II study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for Stage III non-small cell lung cancerStage III non-small cell lung cancerJPRN-UMIN000010428West Japan Oncology Group44
Completed
Not Applicable
Observational study of FOLFOX therapy for esophageal squamous cell carcinomaJPRN-UMIN000044485Shizuoka Cancer Center93
Not yet recruiting
Phase 1
Phase I study of definitive chemoradiotherapy with paclitaxel, CDDP and 5-FU (PCF-RT) for clinical stage IA-IIIC esophageal canceresophageal cancerJPRN-UMIN000028589Osaka international cancer institute24
Recruiting
Phase 1
Phase I study of definitive CRT with paclitaxel, CDDP and 5-FU for clinical stage IA-IIIC esophageal cancer.(PCF-RT)Esophageal cancerJPRN-jRCTs051180082Yamamoto Sachiko24